Non-interventional Study Describing Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms SPAF
- Sponsors Boehringer Ingelheim
- 02 Feb 2018 Planned End Date changed from 18 Jun 2018 to 19 Jul 2018.
- 02 Feb 2018 Planned primary completion date changed from 18 Jun 2018 to 19 Jul 2018.
- 02 Feb 2018 Status changed from recruiting to active, no longer recruiting.